Clinical trials: CtDNA
Lung Cancer, Pulmonary Neoplasm
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.
- Trial name
- BioMolCTC (NCT06546007)
- Testing
- CTC-DNA
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Rarecells Diagnostics SAS
Colorectal Cancer, Colorectal Adenoma
A Study on a Blood-based Dual-target Test for CRC Detection
To evaluate the effectiveness and accuracy of the ctDNA dual-target test kit in a large case-control cohort for the detection of colorectal cancer and advanced adenomas.
- Trial name
- NCT05508503
- Testing
- Test of methylated NTMT1 and MAP3K14-AS1, FIT
- Where
- China
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Melanoma (Skin Cancer)
A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.
This is a phase II pilot study evaluating the use of circulating tumor DNA (ctDNA) to guide the optimal duration of standard of care immune checkpoint inhibitor (ICI) therapy in patients with unresectable and/or metastatic…
- Trial name
- NCT07830225
- Testing
- A Pilot Study of ctDNA-guided immune checkpoint inhibitor duration in patients with advanced melanoma
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Rutgers, The State University of New Jersey
Glioblastoma
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years)…
- Trial name
- NCT05502991
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Provincial People's Hospital
Colorectal Cancer
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient.
- Trial name
- NCT06098560
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Acute Leukemia
CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia
This study will monitor CtDNA After Chemotherapy in Elderly Patients With AL
- Trial name
- NCT04157569
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Navy General Hospital, Beijing
Prostate Cancer Recurrence After Radical Prostatectomy
Targeted Radiotherapy for Recurrent Prostate Cancer
The TASTEPRO pilot trial evaluates the feasibility of PSMA PET-CT (Computer tomography) targeted stereotactic radiation therapy (SABR) in management of lymph node positive prostate cancer recurrence after radical prostatectomy.
- Trial name
- TASTEPRO (NCT05067660)
- Testing
- Stereotactic ablative radiotherapy, Current standard template-based salvage therapy
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Tampere University Hospital
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Lung Squamous Cell Carcinoma
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell…
- Trial name
- NCT05778253
- Testing
- WES and ctDNA detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Xiangya Hospital of Central South University
Colon Adenocarcinoma, Stage I Colon Cancer
Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma
This multicenter prospective observational cohort study will enroll 392 patients with stage I-III colon adenocarcinoma who undergo curative resection and whose tumors harbor at least one prespecified oncogenic driver mutation…
- Conditions
- Colon Adenocarcinoma, Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
- Trial name
- ADX-DRIVER-CRC (NCT07795528)
- Testing
- Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Plasma ctDNA Monitoring in Pediatric Acute Leukemia
This retrospective-prospective observational cohort study aims to evaluate peripheral blood plasma circulating tumor DNA (ctDNA) dynamics in pediatric acute leukemia and compare ctDNA results with concurrent bone marrow…
- Trial name
- NCT07751588
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.
- Conditions
- Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases
- Trial name
- MAGNETIC1 (NCT05814224)
- Testing
- Liquid biopsy and CT scan
- Where
- 7 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Lung Cancer
Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer
This study aims to promote the rational use of liquid biopsy in the clinical detection of lung cancer. Lung cancer is a malignant tumor with high morbidity and mortality worldwide.
- Trial name
- LUNGCA (NCT03317080)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- West China Hospital
Primary Mediastinal Large B-cell Lymphoma
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of…
- Trial name
- CAMIL (NCT04824950)
- Testing
- Circulating tumor DNA monitoring
- Where
- 2 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Henri Becquerel
Endometrial Cancer
Signatera Assessment in Early-Stage Endometrial Cancer
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer.
- Trial name
- SIGNAL-EMC 101 (NCT07339384)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Where
- 12 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- Natera, Inc.
Hepatocellular Carcinoma Resectable
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can…
- Trial name
- NCT06157060
- Testing
- circulating tumor DNA
- Where
- 7 sites in China
- Volunteers
- 255 people
- Sponsor
- Zhujiang Hospital
Colon or Upper Rectum Adenocarcinoma
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
Phase III multicentric, open-label, randomized study The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment…
- Trial name
- CIRCULATE PAC (NCT06197425)
- Testing
- "FOLFIRI" cures, Trifluridine cures, BIOLOGICAL ASSESSMENT
- Where
- France
- Volunteers
- 1,660 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hodgkin Lymphoma, Hodgkin Disease
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic…
- Conditions
- Hodgkin Lymphoma, Hodgkin Disease, Advanced Hodgkin Lymphoma
- Trial name
- FINISH-HL (NCT07209059)
- Testing
- Nivolumab, N-EACOPD-14, N-AVD
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- National Research Center for Hematology, Russia
Non-small Cell Lung Cancer
ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
The goal of this observational study is to explore whether ctDNA-MRD dynamic monitoring can more effectively predict the therapeutic effect of induction chemoimmunotherapy followed by surgery or non-surgical treatment for stage…
- Trial name
- NCT05822284
- Testing
- NGS and ctDNA-MRD detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Xiangya Hospital of Central South University